Physician profile
Stuart L Cooper
NPI 1942223086
$5,221.14
in general payments reported to CMS, 2019-2025
41 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $183 · 2022: $637 · 2023: $1,422 · 2024: $1,056 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $655.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $571.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $415.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $377.37 | 2019-2025 | |
| Amgen INC. | $350.72 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $293.50 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.40 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $209.77 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $206.71 | 2023-2025 | Ingrezza |
| Dexcom, INC. | $203.34 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $135.39 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $133.22 | 2019-2025 | |
| Daiichi Sankyo INC. | $126.48 | 2020-2025 | Injectafer |
| Glaxosmithkline, LLC. | $117.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.98 | 2019-2025 | Jardiance |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.